Citius Pharmaceuticals, Inc. (CTXR)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 09-30. Amounts in USD.

Revenue Annual

0 35K 70K 105K FY21: 90K FY22: 90K FY21 FY22

Gross Profit Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Annual

-45M -30M -15M 0 15M 30M 45M FY24: -42M FY25: -38.5M FY24 FY25

Net Income Annual

-45M -30M -15M 0 15M 30M 45M FY24: -39.4M FY25: -39.7M FY24 FY25

Cost of Revenue Annual

0 30K 60K 90K FY17: 50K FY18: 75K FY17 FY18

Operating Cash Flow Annual

-30M -20M -10M 0 10M 20M 30M FY24: -28.2M FY25: -26.6M FY24 FY25

Free Cash Flow Annual

-27M -18M -9M 0 9M 18M 27M FY20: -16.9M FY21: -24.3M FY20 FY21

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 4M 8M 12M FY24: 6.7M FY25: 11.1M FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q4 '24: -5.96 Q1 '25: -5.81 Q2 '25: -5.74 Q3 '25: -4.97 Q4 '25: -3.48 Q1 '26: -2.56 Q2 '26: -2.24 Q3 '26: -1.78 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26 Q3 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.